Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Procedural Sedation During TAVR (Remifentanil/Dexmedetomidine/Propofol/Ketamine)
2024-511018-18-00Phase 3Authorised
- Sponsor
- ASST Ovest Milano
- Start
- Jul 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in aortic stenosis (AS) and cardiac morbidity comparing Remifentanil + Propofol, Dexmedetomidine + Propofol and Ketamine + Propofol (3 arms). Primary endpoints: Incidence of respiratory acidosis and Incidence of emergence delirium. Planned start Jul 2024; status: authorised.
02
Drugs
remifentanildexmedetomidinepropofolketamine
03
Conditions
aortic stenosis (AS)cardiac morbidity
Beyond the preview
Go deeper on 2024-511018-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511018-18-00.